Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.046,80+0,37 %

Gold3.292,100,00 %

Öl (Brent)62,89-1,66 %

Dow Jones42.234,95+0,10 %

US Tech 10021.338,70-0,05 %

EUR/USD1,13485-0,20 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Mirum Pharmaceuticals Aktie

Aktie

ISIN: US6047491013 WKN: A2PM29 SYM: 08D Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

39,20

EUR

+1,55 %

+0,60 EUR

Letzter Kurs 30.05.25 Tradegate

Mirum Pharmaceuticals Aktie kaufen

Geldkurs

30.05.25

38,20

EUR

157 STK

Briefkurs

30.05.25

40,00

EUR

149 STK

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer 19.05.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences 14.05.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10.05.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL 09.05.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update 07.05.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 30.04.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses 28.04.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation 14.04.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11.04.25 · Business Wire (engl.) · Mirum Pharmaceuticals
LIVMARLI Now Approved in Japan for ALGS and PFIC 27.03.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11.03.25 · Business Wire (engl.) · Mirum Pharmaceuticals
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update 26.02.25 · Business Wire (engl.) · Mirum Pharmaceuticals

1
2
3
…
4

Meistgelesen

30 Tage
12 Monate

Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL 124 Leser
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer 124 Leser
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update 116 Leser
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 112 Leser
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences 104 Leser

Fokus Aktien mit extremen Handelsvolumen am Dienstag, den 18.06.2024 428 Leser
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies 220 Leser
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat ... 192 Leser
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses 180 Leser
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and ... 176 Leser
LIVMARLI Now Approved in Japan for ALGS and PFIC 156 Leser
LIVMARLI von Mirum Pharmaceuticals wird in der Europäischen Union für Patienten mit PFIC ... 156 Leser
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at ... 152 Leser
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 148 Leser
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update 144 Leser

	
		OSZAR »